Responsibility & ESG

ESG Highlights 2022

ENVIRONMENT

  • Expansion of the photovoltaic system from 20 kWp to 28 kWp
  • 16% of electricity consumption covered by own photovoltaic system in 2022
  • Gas consumption reduced by 54.8% compared to the same period of the previous year due to savings measures

SOCIAL

  • Gender Diversity Index Austria 2022: Marinomed again among top three in 3rd place
  • Human resources department strengthened
  • CSO Eva Prieschl-Grassauer was awarded the Golden Decoration of Merit of the Republic of Austria for her scientific achievements and their translation into commercial success

GOVERNANCE

  • Presented a sustainability report for the first time in 2022 for the 2021 financial year
  • Strengthening of inhouse legal advice with corporate counsel
  • Redesign of corporate website for even more transparency

Sustainability Report 2022

Sustainability at Marinomed

We are convinced that we can only be successful in the long term through sustainable developments. In all our decisions, we consider aspects that are not only beneficial for the Company or our stakeholders, but are also guided by the impact our actions have on our employees, our environment and our reputation as a Company.

Our vision and primary goal is to protect and improve the health and well-being of people. With our technologies and innovations, we want to address diseases that have so far been insufficiently treated, improve existing therapies and give as many people as possible access to high-quality treatments. With this objective, we pursue a sustainable strategy from the ground up. This continues in the other aspects of our corporate governance, as this report will show. Decisions are continuously reviewed for sustainability aspects and regularly addressed by the Management Board and Supervisory Board. We also intend to incorporate sustainability criteria into important corporate guidelines, such as the remuneration policy and the rules of procedure for the Management Board and Supervisory Board. For example, the Supervisory Board has already linked parts of the variable remuneration of the Management Board for 2022 to the sustainable development goals of the Company.

The Company has extensive expertise in virology and immunology and an active pipeline based on its Carragelose and Marinosolv technology platforms. The success of its product development is reflected in a marketed OTC portfolio as well as other products already in the authorization process. We are working hard on translating our expertise into innovation and thus make our contribution to a future worth living.

Overview of the most important SDG goals that Marinomed pursues with its sustainability strategy. The length of the rays corresponds to the importance of the topics for Marinomed.

Corporate Governance

Marinomed is committed to the rules of the Austrian Corporate Governance Code in the version of January 2018 and complies with all rules required by law (L-Rules) and to a large extent with the rules required by the Code (C-Rules). C-Rules that have not yet been fully complied with are consistently reviewed and their treatment explained in the Corporate Governance Report. 

Whistleblower system

Misconduct at Marinomed - especially systematic misconduct - has not been tolerated in the past and will not be tolerated in the future. Nevertheless, it cannot be ruled out that we observe behaviour in our daily work that we may judge to be misconduct or wrongdoing. We have set up a system that provides employees of Marinomed as well as external contractors or other stakeholders with the opportunity to report incidents that they judge to be misconduct or wrongdoing. We would like to encourage you to make an active and valuable contribution so that we can jointly identify and remedy any misconduct and wrongdoing and thus meet the high standards we set ourselves.

Directors’ Dealings:

20.04.2023 - Brigitte Ederer / Member of an administrative or supervisory board
(146 KB)
15.09.2022 - Brigitte Ederer / Member of an administrative or supervisory board
(134 KB)
15.12.2021 - Brigitte Ederer / Member of an administrative or supervisory board
(76 KB)
02.12.2021 - Pascal Schmidt / CFO
(187 KB)
02.12.2021 - Andreas Grassauer / CEO
(187 KB)
02.12.2021 - Eva Prieschl-Grassauer / CSO
(187 KB)
16.12.2020 - Eva Prieschl-Grassauer / CSO
(732 KB)
16.12.2020 - Pascal Schmidt / CFO
(732 KB)
16.12.2020 - Andreas Grassauer / CEO
(733 KB)
27.01.2020 - Brigitte Ederer / Member of an administrative or supervisory board
(301 KB)
18.10.2019 - Karl Lankmayr / Member of an administrative or supervisory board
(304 KB)
18.10.2019 - Gernot Hofer / Member of an administrative or supervisory board
(303 KB)
20.02.2019 - Ute Lassnig / Member of an administrative or supervisory board
(305 KB)
20.02.2019 - Simon Nebel / Chairman of the supervisory board
(304 KB)
01.02.2019 - Karl Lankmayr / Member of an administrative or supervisory board
(43 KB)
01.02.2019 - Gernot Hofer / Member of an administrative or supervisory board
(43 KB)
31.01.2019 - Simon Nebel / Chairman of the supervisory board
(42 KB)
30.01.2019 - Ute Lassnig / Member of an administrative or supervisory board
(22 KB)
Lucia Ziegler, MSc
Head of Investor & Public Relations
Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg, Austria
+43 2262 90300
office@marinomed.com